Telangana Police signs MOU to support LGBTQIA+ community
The two entities signed a Memorandum of Understanding (MoU) aimed at strengthening the Pride Place – Transgender (LGBTQIA+) Persons Protection Cell. This collaboration is expected to provide services, including - crisis intervention, mental health support, legal aid, and public awareness campaigns.
As part of the agreement, Yugantar will extend the resources of its Queer-Trans Wellness and Support Centre in Hyderabad to aid vulnerable individuals. The organisation will also assist in training police personnel to handle cases involving LGBTQIA+ persons with greater sensitivity and care.
The MoU was signed by Additional Director General of Police, Telangana Women Safety Wing, Charu Sinha.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Mint
4 hours ago
- Mint
Layoffs loom at weight loss drug Wegovy's maker Novo Nordisk as slowing sales threaten job cuts
COPENHAGEN, Aug 21 (Reuters) - As Novo Nordisk's sales of its blockbuster weight-loss drug Wegovy boomed, the Danish drugmaker raced to expand manufacturing capacity and sales outreach with a hiring spree that almost doubled staff numbers over five years. Now sales are slowing and layoffs loom. Annual reports show that Novo's workforce grew from around 43,260 employees in 2019 to 77,350 by the end of last year - an average of 131 new roles filled each week, far faster than rival Eli Lilly, whose headcount rose from 36,000 to 47,000 over the same period. Novo's rapid expansion is now under scrutiny from investors and even management, with the drugmaker facing cost pressure and heightened competition from Lilly's Zepbound and cheaper weight loss copycat compounds in the United States. "I don't want to limit myself in terms of where I look for savings, and salaries are a cost item. I will go through everything," said CEO Maziar Mike Doustdar on August 7, his first day in the job. Two weeks later, on Wednesday, Novo said it had implemented a global hiring freeze for non-critical roles. When asked for details of headcount reduction plans, a company spokesperson referred Reuters to Doustdar's comments. The five-year hiring surge saw employee costs almost double to nearly $9.9 billion by last year, company filings show. While the increased overhead barely registered as sales shot up, Novo's gross margin has been squeezed this year, reaching its lowest level in two and a half years in the second quarter. The stock market has wiped $490 billion off the company's market capitalisation since a peak last year when it was Europe's most valuable firm. It appointed Doustdar to turn things around after twice warning on profit this year and saying sales could dip in the second half of 2025 from a year earlier. "Their earnings had been so strong that you could ignore the cost side," said Lars Hytting, head of trading at Denmark-based investment firm ArthaScope, which holds Novo shares, adding the firm had grown "complacent" and now needed to slim down. 'Novo is now going on Wegovy.' SALES JOBS SEEN AT RISK Some analysts anticipate layoffs in the sales division - a common industry cost-cutting measure. Novo hinted at this during its second-quarter results, saying it would begin deprioritising sales of Rybelsus, its older type 2 diabetes treatment. Sales of the drug have declined, eclipsed by soaring demand for Ozempic, which shares the same active ingredient as Wegovy. "That is probably not a coincidence," said TD Cowen analyst Michael Nedelcovych. "When companies try to cut costs, they probably look first to a sales force for an ailing drug." Novo built a new U.S. sales force to market Wegovy to doctors rather than rely on staff who were already promoting Ozempic, three former employees familiar with the drug's launch told Reuters. That meant more costs, and at times the teams overlapped in outreach to the same healthcare providers, they said. All asked not to be named in order to speak frankly about a former employer. The Novo Nordisk spokesperson declined to comment on the structure of its business. In response to the initial unprecedented demand for Wegovy, Novo also invested billions to expand factories in Denmark and the United States. The company said in early 2024 that around 70% of new hires in the previous two to three years were in the manufacturing division. The spokesperson said that last year, 49% of new hires were related to manufacturing, including around 3,200 employees from Catalent, a contract drugmaker acquired last year by Novo Holdings, Novo Nordisk's controlling shareholder. Novo could also first turn to functions such as communications or administrative roles for cuts, because reductions in sales or manufacturing could hinder its ability to regain market share, said Simon Birkso Larsen, founder and head of Pipeline Clarity, a Copenhagen-based pharmaceutical industry consultancy that does not count Novo as a client. Larsen was a Novo Nordisk employee from 2015 to 2017. "Novo hired so rapidly that it has become difficult to figure out who does what in the are limits to how many people you can integrate and still be effective," he said. ($1 = 6.3995 Danish crowns) (Reporting by Maggie Fick and Jacob Gronholt-Pedersen; Editing by Adam Jourdan, Michele Gershberg and Kirsten Donovan) Disclaimer: This story has been published from a wire agency feed without modifications to the text. Only the headline has been changed.
&w=3840&q=100)
Business Standard
5 hours ago
- Business Standard
Nova IVF Fertility introduces AI into IVF labs for precise embryo selection
Nova IVF Fertility has introduced an artificial intelligence (AI)-driven embryo assessment tool, Vita Embryo, across its 120 clinics in 65 cities. The aim is to improve success rates and bring greater accuracy to IVF treatments. The technology, developed in partnership with South Korea–based Kai Health, is designed to help doctors make more precise embryo selections for patients. The Bengaluru-headquartered company stated that the adoption of AI is expected to improve pregnancy rates, shorten the duration of IVF cycles, and increase transparency in fertility treatments. 'With fertility rates declining in countries like India and 1 in 6 couples struggling to conceive, the need for precision in fertility treatment is more pressing than ever. Nova IVF has always been at the forefront of implementing technology. Our IVF labs follow European standards of embryology protocols,' said Shobhit Agarwal, CEO of Nova IVF Fertility. 'With the use of Artificial Intelligence, we aim to improve the chances of successful pregnancies and reduce the turnaround time of IVF cycles. Improved precision can also reduce the number of embryos needed for transfer, addressing ethical concerns related to multiple pregnancies. We believe that advanced technologies like this should be accessible to all patients in metro and tier-2 regions, without any additional monetary charges,' Agarwal added. Kai Health has secured medical device certification for Vita Embryo in Europe, Singapore, Korea, and India. Clinical trials suggest the AI-powered tool can double the accuracy of embryo selection compared to human evaluation, potentially offering couples a better chance of achieving a successful pregnancy. Hyejun Lee, CEO of Kai Health, said, 'Our research indicates that with the intervention of AI, the precision of selecting embryos increased by 12%. Our partnership with Nova IVF Fertility marks our readiness for global market expansion. We will continue to focus on technological excellence and clinical impact by partnering with leading IVF networks worldwide.' Nova highlighted that a survey by Kai Health demonstrated that AI can improve the precision of embryo selection by 12 per cent. The company added that adopting the technology would also bring greater transparency for patients and couples undergoing fertility treatment. India's infertility rate stood at 1.9 in 2021, below the replacement level rate of 2.1, according to Lancet data. Notably, India's egg-freezing and embryo-banking market, valued at $206 million in 2023, is projected to grow at a compound annual growth rate (CAGR) of 17.4 per cent, reaching $632.5 million by 2030, according to a study by Grand View Research.
Time of India
6 hours ago
- Time of India
12 reasons to remind your boss why working extra hours is bad for both of you
Across industries, working late has long been seen as proof of commitment. Yet experts warn that the habit often does more harm than good, draining energy, straining relationships, and reducing long-term productivity . With conversations around work-life balance becoming more urgent, professionals are now challenging the belief that staying past office hours is a measure of success. Adding to this discussion, London-based entrepreneur Dan Murray outlined twelve reasons why leaving on time benefits not only employees but also their organisations. Taking to LinkedIn, Murray argued that while work will always remain, the time spent on family, self-care, and personal pursuits cannot be regained. He described overwork as an unsustainable habit that may initially appear productive but ultimately reduces efficiency and erodes quality of life. by Taboola by Taboola Sponsored Links Sponsored Links Promoted Links Promoted Links You May Like Join new Free to Play WWII MMO War Thunder War Thunder Play Now Murray's 12 Reasons to Leave on Time In his post, Murray outlined twelve reasons why employees should not sacrifice personal time for extended office hours. His list emphasised that: Work is a continuous process and will never be fully completed. Mental and physical health must remain a priority. Time with family and friends is invaluable. Rest and recovery are essential for productivity. Setting boundaries protects personal space. A balanced lifestyle enhances overall well-being. Burnout is real and damaging. Hobbies and passions provide fulfilment. Exercise and self-care strengthen resilience. A job does not define identity. Life is too short to spend solely at work. True happiness comes from safeguarding well-being. He concluded that employees who take care of themselves outside work return more motivated and contribute more effectively to their teams. You Might Also Like: Long duty hours, night shifts but she still cracked UPSC. Meet doctor-turned-IAS office Dr Anjali Garg, from Delhi Safdarjung Hospital Online Reactions to the Post Murray's reflections quickly gained traction, drawing thousands of views and hundreds of comments within days. Many professionals echoed his views, agreeing that long hours are often mistaken for dedication but, in reality, diminish creativity and energy. One user wrote that boundaries and rest are what sustain enthusiasm and innovation at work. Another described protecting personal time as one of the smartest long-term investments in both career and life. Others noted that balance helps regulate mental and physical health, making individuals more effective in the long run. Some described Murray's post as more than just advice, calling it a practical manifesto for sustainable success. A commenter noted that leaving on time should not be seen as laziness but as an example of leadership and healthy ambition. You Might Also Like: Boss refuses WFH amid Mumbai rains. But employee's two-word reply shuts him down Who Is Dan Murray? According to his LinkedIn profile, Murray studied English and Art History at the University of Nottingham after completing his schooling at University College School. He co-founded a fashion-focused mobile app that ran for more than four years before moving on to other ventures. Over the years, he has launched or co-founded several start-ups, building a reputation as a founder who advocates both professional innovation and personal balance.
